Evidence map›Paper›PMID 37928429›Full record

ArticleJournal of Cancer2023

High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis.

Yufeng Li, Yajun Li, Ruolan Zeng, Yizi He, Liang Liang, Lijia Ou, Chang Su, Hui Zhou, Ling Xiao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yufeng LiCentral South University, Department of Lymphoma & Hematology, The Affiliated Tumor Hospital of Xiangya Medical School, Changsha, Hunan, China.
Yajun LiCentral South University, Department of Lymphoma & Hematology, The Affiliated Tumor Hospital of Xiangya Medical School, Changsha, Hunan, China.
Ruolan ZengCentral South University, Department of Lymphoma & Hematology, The Affiliated Tumor Hospital of Xiangya Medical School, Changsha, Hunan, China.
Yizi HeCentral South University, Department of Lymphoma & Hematology, The Affiliated Tumor Hospital of Xiangya Medical School, Changsha, Hunan, China.
Liang LiangCentral South University, Department of Lymphoma & Hematology, The Affiliated Tumor Hospital of Xiangya Medical School, Changsha, Hunan, China.
Lijia OuDepartment of Histology and Embryology of School of Basic Medical Science, Central South University, Changsha, Hunan, China.
Chang SuDepartment of Histology and Embryology of School of Basic Medical Science, Central South University, Changsha, Hunan, China.
Hui ZhouCentral South University, Department of Lymphoma & Hematology, The Affiliated Tumor Hospital of Xiangya Medical School, Changsha, Hunan, China.
Ling XiaoDepartment of Histology and Embryology of School of Basic Medical Science, Central South University, Changsha, Hunan, China.
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bruton tyrosine kinasecentral nervous system diffuse large B-cell lymphomactDNAorelabrutinib

Identifiers

PMID37928429
PMCPMC10622989
OpenAlexW4387194621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.